DUNEDIN, New Zealand, April 12, 2017 /PRNewswire/ -- Pacific Edge is proud to announce that its recent clinical study on Cxbladder Monitor's clinical performance and utility has been published in the ...

Cancer diagnostics company, Pacific Edge, has provided an update on its key strategic milestones and Q3 2026 results. The company highlighted the upcoming Medicare Administrative Contractor Novitas' ...

Providers using BxLink can easily access Cxbladder's suite of tests, allowing faster integration of these groundbreaking diagnostics into everyday practice. The platform's advanced capabilities ensure ...

DUNEDIN, New Zealand and HERSHEY, Pa., May 28, 2014 /PRNewswire/ -- Pacific Edge announced today that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostic laboratory testing ...

Pacific Edge Limited (NZX:PEB), a cancer diagnostics company developing and commercializing a suite of non-invasive tests for the detection and management of bladder cancer, announces today the ...

Pacific Edge, a cancer diagnostic company, has signed an agreement with FedMed, a provider network in the United States, to make Cxbladder available. The agreement provides FedMed's contracted ...

Pacific Edge (PEB), a cancer diagnostics company, today released its investor update for the three months ending December ...

Bladder cancer is the ninth most common cancer globally and the fifth most common in the United States. Although bladder cancer can often be treated successfully, it has one of the highest recurrence ...

Biomarkers have value in the diagnosis and monitoring of bladder cancer, but their use is still being perfected. The value of using biomarkers in bladder cancer is compelling, though experts in the ...